On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.

On the news front, the company's core drug candidate obefazimod faced persistent safety concerns stemming from its Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dosage group. The stock had previously plunged from around $130 to approximately $70 — a decline of nearly 50%. Some investors subsequently argued the cancer cases were more likely age-related and that the initial selloff was excessive, driving a partial rebound above $100. However, the market remains divided on the safety implications, and as technical rebound momentum continues to weaken, the stock has resumed its downward trajectory.

Within the Biotechnology sector, among notable peers, AbbVie rose 3.09%, Revolution Medicines rose 4.94%, Ascendis Pharma rose 9.0%, Apogee Therapeutics rose 0.01%, while Gilead Sciences fell 0.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)